Verona Pharma's Upcoming Financial Disclosure and Updates
Verona Pharma's Upcoming Financial Disclosure
Verona Pharma plc (NASDAQ: VRNA), a leading biopharmaceutical company, is set to reveal important financial results for the third quarter ended September 30, 2024. The announcement will be made on Monday, November 4, 2024. A pivotal conference call is scheduled for 9:00 a.m. EDT / 2:00 p.m. GMT where executives will discuss the financial outcomes and share key corporate updates.
Joining the Conference Call
Investors and interested participants wishing to join the call can do so by dialing either of the following numbers:
United States Callers
For those located in the United States, please call +1-833-816-1396.
International Callers
International participants can reach out at +1-412-317-0489. Remember to ask for the Verona Pharma call upon connection.
Live Webcast Availability
A live audio webcast of the conference will also be accessible through the Events and Presentations link on the investor section of Verona Pharma's website. Participants will have the chance to access the audio replay of the conference call for a period of 90 days following the event.
Contact Information for Inquiries
For any inquiries regarding the financial results or further information, please reach out to:
Verona Pharma plc
Tel: +1-844-341-9901
Investor Relations
Victoria Stewart, Senior Director of Investor Relations and Communications
Email: [email protected]
U.S. Investor Inquiries
Argot Partners
Tel: +1-212-600-1902
Email: [email protected]
Media Inquiries
Ten Bridge Communications
Tel: +1-312-523-5016
Email: [email protected]
About Verona Pharma
Verona Pharma is committed to developing innovative therapies aimed at treating chronic respiratory diseases where there is a significant unmet need. Their flagship product, Ohtuvayre™ (ensifentrine), represents a breakthrough as the first inhaled medication that combines bronchodilator and anti-inflammatory properties into a single treatment for COPD. This dual action may extend to other serious respiratory conditions, including chronic bronchiectasis and asthma.
Frequently Asked Questions
When will Verona Pharma announce their Q3 financial results?
Verona Pharma intends to announce their financial results for Q3 on November 4, 2024.
How can I participate in Verona Pharma's conference call?
Participants can join by calling +1-833-816-1396 for U.S. callers or +1-412-317-0489 for international callers.
Where can I find the live webcast of the conference?
The live webcast will be accessible via the Events and Presentations link on Verona Pharma's investor page.
What is Ohtuvayre™?
Ohtuvayre™ (ensifentrine) is Verona Pharma's first product, designed for the maintenance treatment of COPD, combining both bronchodilator and anti-inflammatory effects.
Who can I contact for more information?
You can contact Verona Pharma's investor relations through Victoria Stewart at +1-844-341-9901 or via email at [email protected].
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Niu Technologies Prepares to Release Q3 2024 Financials
- MYCOM OSI Welcomes New Leaders: Andrew Coll and Charles Bligh
- Eckoh Plc and Investec Bank: Insights on Recent Dealings
- Investec Bank Forms Essential Disclosure for Brown Group plc Deal
- NIANCE Launches Innovative Insights on Aging and Wellness
- Market Movements: Mixed Futures and Earnings Anticipation
- Upcoming Economic Events: What to Watch in Market Shifts
- Sydbank's Ongoing Buyback Efforts and Recent Transactions
- Evosep Enhances Support for Pharma and Biotech Growth
- iliad SA Initiates Tender Offer for Bonds and Plans New Green Bonds
Recent Articles
- European Energy A/S Announces Conditional Early Bond Redemption
- Exor N.V. Updates on Recent Share Buyback Activities
- Smiths Detection Achieves Unique Certification for Security Tech
- eLstar Dynamics Introduces Revolutionary Dynamic Glass at Glasstec
- Agilent Unveils Innovative Infinity III LC Series for HPLC
- Faraday Future Launches a Creative Contest for FX Logo Design
- Seaport Therapeutics Successfully Raises $225 Million in Series B
- JAB Boosts JDE Peet’s Free Float Through Strategic Share Moves
- Seaport Therapeutics Secures $225 Million to Advance Mental Health Treatments
- Lazard Welcomes Fabien Antignac to Lead European Debt Solutions
- Great Bay Bio's Revolutionary Drug Development Ecosystem Unveiled
- Akkodis Achieves Zinnov Leader Status for Digital Engineering
- BWH Hotels and Mews: A Transformative Partnership for Innovation
- McDermott Achieves Platinum Status in Garnet Recycling Leadership
- Thunes Empowers Banks with Mobile Wallet Payment Solutions
- YogaEasy Unveils Exciting New Online Platform for Yoga Lovers
- Rockit Global's Partnership with Kung Fu Panda: A Delightful Venture
- Akkodis Awarded as Leader in ER&D and Digital Engineering
- Dr. Joleen Liang: Leading the AI Transformation in Education
- Tan Dun: Journey from Hunan Villager to Global Music Icon
- DNB's Strategic Acquisition of Carnegie Valued at $1.14 Billion
- Bitcoin Soars to $69K: Trump Speculation Fuels Cryptocurrency Rise
- Unlocking Financial Growth: Top ETFs for Lifelong Investments
- Insights from Fabricio Bloisi on Prosus' Vision and Growth
- ONWARD Medical Welcomes Industry Experts to Board Leadership
- Vallourec Partners with ASMO to Enhance Supply Chain Solutions
- Sanofi and CD&R Collaborate to Elevate Opella in Healthcare
- UBS Divests Swisscard Stake to American Express in Strategic Move
- Australian Stocks Surge: S&P/ASX 200 Sees Notable Gains
- Sanofi Negotiates Sale of Opella to Clayton Dubilier & Rice
- Virtualware Expands Horizons with Strategic Acquisition of Simumatik
- ONWARD Medical Welcomes New Leaders to its Board of Directors
- Vallourec and ASMO Form Game-Changing Alliance for Energy
- Sanofi and CD&R Partner to Elevate Opella in Consumer Health
- FORVIA Reports Q3 2024 Sales With Strong Growth Amid Challenges
- Cabka Reports Positive Q3 Sales Growth Amidst Challenges
- Boussard & Gavaudan Holding Limited Update on NAV Metrics
- Boussard & Gavaudan Holding Limited: Updated NAV Details
- Sampo plc Expands Share Buyback Program Amid Market Changes
- Thailand Sees Surge in Investment Applications Amid Tech Boom
- ARC Group: A Leader in Investment Advisory Services Industry
- Global Economic Outlook: IMF and World Bank Face Challenges
- Understanding the Dynamics of ASML and TSMC in Semiconductors
- Bigbank AS Secures Success with Unsecured Bond Offering
- VEON Achieves Compliance with Nasdaq After Recent 20-F Filing
- LHV Pank Expands Through Strategic Acquisition of Loans
- Galderma's Latest Findings Showcase RelabotulinumtoxinA Efficacy
- Trailstone and Eurowind Energy Collaborate to Boost Renewables
- VEON Achieves Nasdaq Compliance After 2023 20-F Filing Success
- AI Technology Expansion: Key Insights and Market Predictions